Publicacions recents

Llista de publicacions més recents liderades per la Unitat de Memòria de l’Hospital de Sant Pau:

  1. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Lleó, A, Zetterberg, H, Pegueroles, J et al. Nat Commun 2021
    PMID:34262030

  2. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. Bejanin, A, Iulita, MF, Vilaplana, E et al. JAMA Neurol 2021
    PMID:34228042

  3. Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. Altuna, M, Giménez, S, Fortea, J et al. J Clin Med 2021
    PMID:34202784

  4. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Lleó, A, Carmona-Iragui, M, Videla, L et al. Alzheimers Res Ther 2021
    PMID:34183050

  5. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Alcolea, D, Delaby, C, Muñoz, L et al. J Neurol Neurosurg Psychiatry 2021
    PMID:34103344

  6. Biomarkers in neurological disorders: a fast-growing market. Lleó, A Brain Commun 2021
    PMID:33977270

  7. AMYQ: An index to standardize quantitative amyloid load across PET tracers. Pegueroles, J, Montal, V, Bejanin, A et al. Alzheimers Dement 2021
    PMID:33797846

  8. Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. Illán-Gala, I, Falgàs, N, Friedberg, A et al. JAMA Netw Open 2021
    PMID:33704477

  9. Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Illán-Gala, I, Casaletto, KB, Borrego-Écija, S et al. Alzheimers Dement 2021
    PMID:33590953

  10. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Illán-Gala, I, Lleo, A, Karydas, A et al. Neurology 2021
    PMID:33199433

  11. Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. Montal, V, Vilaplana, E, Pegueroles, J et al. Alzheimers Dement 2021
    PMID:33196147

  12. Heterozygous APOE Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes. Hernandez, I, Gelpi, E, Molina-Porcel, L et al. Neuropathol Appl Neurobiol 2021
    PMID:33095930

  13. Genetic-environmental factors finally assessed together in Parkinson's disease. Clarimón, J J Neurol Neurosurg Psychiatry 2020
    PMID:32934106

  14. Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Illán-Gala, I, Montal, V, Pegueroles, J et al. Neurology 2020
    PMID:32913016

  15. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. Belbin, O, Xiao, MF, Xu, D et al. Mol Neurodegener 2020
    PMID:32807227

  16. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Dols-Icardo, O, Montal, V, Sirisi, S et al. Neurol Neuroimmunol Neuroinflamm 2020
    PMID:32669313

  17. Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. Benejam, B, Videla, L, Vilaplana, E et al. Alzheimers Dement (Amst) 2020
    PMID:32613076

  18. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J, Vilaplana, E, Carmona-Iragui, M et al. Lancet 2020
    PMID:32593336

  19. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Delaby, C, Alcolea, D, Carmona-Iragui, M et al. Sci Rep 2020
    PMID:32514050

  20. Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. Cervera-Carles, L, Dols-Icardo, O, Molina-Porcel, L et al. Neurobiol Aging 2020
    PMID:32335360

  21. Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. Cantero, JL, Atienza, M, Lage, C et al. Cereb Cortex 2020
    PMID:31799623

  22. APP-derived peptides reflect neurodegeneration in frontotemporal dementia. Illán-Gala, I, Pegueroles, J, Montal, V et al. Ann Clin Transl Neurol 2019
    PMID:31789459

  23. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alcolea, D, Clarimón, J, Carmona-Iragui, M et al. Alzheimers Dement (N Y) 2019
    PMID:31650016

  24. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Alcolea, D, Pegueroles, J, Muñoz, L et al. Ann Clin Transl Neurol 2019
    PMID:31464088

  25. Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. Carmona-Iragui, M, Videla, L, Lleó, A et al. Dev Neurobiol 2019
    PMID:31278851

  26. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Morenas-Rodríguez, E, Alcolea, D, Suárez-Calvet, M et al. Sci Rep 2019
    PMID:31127154

  27. Nanoscale structure of amyloid-β plaques in Alzheimer's disease. Querol-Vilaseca, M, Colom-Cadena, M, Pegueroles, J et al. Sci Rep 2019
    PMID:30914681

  28. Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Brain 2019
    PMID:30906945

  29. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Lleó, A, Núñez-Llaves, R, Alcolea, D et al. Mol Cell Proteomics 2019
    PMID:33431128

Search PubMed